Cellular Therapies, ADCs & Diagnostics: Cancer Care Costs & Logistics
Summary of the Provided Text:
This text excerpt discusses the challenges faced by clinical pharmacists in delivering efficient and safe cancer care, especially focusing on the hidden costs associated with payer-driven site-of-care restrictions and administrative burdens.
Key Points:
* Site-of-Care Restrictions: Insurance companies are pushing for treatments like IVIG and immunotherapies to be administered outside of hospitals to reduce costs. While this can save money, it leads to care fragmentation, causing patient confusion, anxiety, and loss of continuity of care.
* Safety Concerns: Fragmented data between external facilities and hospitals creates potential safety gaps. It’s difficult to verify if patients actually received their medication and if that facts is communicated back to the care team.
* Administrative Burden & Payer Lag: Pharmacists spend important time navigating formulary approvals, system builds, and insurance authorizations, which often lag behind FDA approvals and clinical guidelines. this delays access to new therapies.
* Pharmacist’s Crucial Role: Pharmacists are vital in operationalizing new therapies, but are hampered by these administrative hurdles.
In essence, the text argues that while payers focus on direct costs, they frequently enough overlook the ”time cost” and potential safety risks created by their policies, ultimately impacting the quality and efficiency of patient care.